• EPZ5676: A Selective DOT1L Inhibitor Workflow

  2026-09-22

  EPZ5676 enables a tightly controlled path from SAM-pocket inhibition to H3K79 methylation loss and leukemia-cell response. This workflow combines biochemical validation, MLL-rearranged models, orthogonal target-engagement assays, and immune-signature controls to improve interpretation and reproducibility.

• Tofacitinib Citrate: Immune Assay Workflows

  2026-09-22

  Build concentration-aware workflows with Tofacitinib citrate for JAK-STAT signaling, lymphocyte proliferation inhibition, and T-cell differentiation studies. A comparative endothelial-cell framework helps researchers separate useful anti-inflammatory activity from high-dose vascular stress signals.

• GS-4997 and Tubulointerstitial Injury in Lupus Nephritis

  2026-09-21

  The reference study identifies ASK1 signaling as a pharmacologically tractable driver of tubulointerstitial injury in lupus nephritis. In female MRL/lpr mice and LPS-stimulated HK-2 cells, GS-4997 reduced inflammation, fibrosis, tubular damage, and downstream p38/JNK activation, supporting further mechanistic investigation rather than establishing a clinical treatment.

• IL-1β Tetrapeptide Controls Inflammatory Caspases

  2026-09-21

  The reference preprint identifies the P4–P1 tetrapeptide adjacent to the canonical IL-1β cleavage site as a determinant of recruitment and productive processing by inflammatory caspases. It also reports direct IL-18 cleavage by human caspases-4/-5 and an apparently inactive IL-1β fragment generated by non-canonical caspases, refining how inflammasome proteases should be interpreted in cytokine and pyroptosis studies.

• Phosphoproteomic Adaptation to Cabozantinib in RCC

  2026-09-20

  This study distinguishes acute from chronic Cabozantinib exposure in renal cell carcinoma by integrating quantitative phosphoproteomics with migration and invasion assays. Its main contribution is a timescale-aware model in which broad cytostatic phosphorylation changes evolve into selective adhesion-, stress-, and MAPK/AP-1-associated remodeling while MET activation-loop phosphorylation remains suppressed.

• ATRA Sensitizes Ovarian Cancer to Niraparib

  2026-09-19

  The reference study shows that all-trans retinoic acid can reduce cisplatin-induced resistance to niraparib in epithelial ovarian cancer models. Its treatment-sequence findings connect retinoid signaling with suppression of an ALDH1A1–NAMPT–PARP1–CHK1 and NAD+-associated resistance state, supporting a maintenance strategy that combines ATRA with PARP inhibition.

• Silymarin Workflows for Translational Research

  2026-09-19

  Silymarin, a chemically diverse milk thistle extract, gives researchers a practical probe for oxidative injury, tumor biology, metabolic dysfunction, and selected antiviral target assays. This guide turns its solubility, mixture composition, and redox activity into controlled workflows with dose-selection, orthogonal validation, and troubleshooting strategies.

• Alpha-Ketoglutarate at the Tumor–Immune Interface

  2026-09-18

  A translational analysis of how α-KGA connects mitochondrial metabolism, PDHA1 succinylation, macrophage antigen presentation, and chemotherapy response in cholangiocarcinoma research.

• CSBTA Pharmacokinetics in MASH Mice

  2026-09-17

  This study shows that HFHCD-induced MASH changes the systemic exposure, hepatic distribution, and hepatocyte accumulation of key Corydalis saxicola Bunting total alkaloids. By combining UHPLC-MS/MS, transporter and microsomal assays, and analyses of CYP450s and PXR-related regulation, the work provides a disease-state framework for interpreting pharmacokinetic variability and optimizing future MASH dosing studies.

• GCRV Entry and Clathrin-Mediated Endocytosis

  2026-09-17

  Wang et al. used pharmacological inhibitors, transmission electron microscopy, and real-time qPCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, acidification-sensitive clathrin pathway. The study also provides an important negative control for IPA-3: under the tested conditions, Pak1-directed inhibition did not measurably block GCRV entry or infection.

• Fluconazole for Reproducible Fungal Assays

  2026-09-16

  This scenario-driven guide explains how Fluconazole, SKU B2094, can support controlled fungal viability, susceptibility, and resistance experiments. It connects mechanism, solvent handling, dose selection, storage, and interpretation to practical laboratory decisions.

• JC-1 Mitochondrial Membrane Potential Assay Kit

  2026-09-16

  Build a ratiometric mitochondrial membrane potential assay around JC-1, CCCP controls, and matched treatment conditions. This practical guide connects mitochondrial depolarization measurements with apoptosis studies of hypoxia-activated cancer therapeutics while emphasizing optimization, controls, and interpretation limits.

• MK-4827: Reframing PARP Inhibition for Translation

  2026-09-15

  A translational perspective on MK-4827 (Niraparib), connecting PARP-1/-2 inhibition, BRCA-associated synthetic lethality, and hyperthermia-induced BRCA2 loss to better experimental design and combination strategy.

• Novobiocin, DNA Replication, and E. faecalis Protoplasts

  2026-09-15

  This study shows that DNA replication is linked to plasma membrane synthesis and vacuole formation during enlargement of Enterococcus faecalis protoplasts. By applying novobiocin at defined stages and tracking DNA content, cell size, and vacuoles, the authors identify a reversible replication-dependent control point in bacterial morphogenesis.

• BicD and MAP7 Activate Drosophila Kinesin-1

  2026-09-14

  This 2025 bioRxiv preprint shows that BicD and MAP7 activate homodimeric Drosophila kinesin-1 through complementary mechanisms. BicD primarily relieves kinesin autoinhibition, whereas MAP7 promotes microtubule recruitment and longer runs, producing the strongest activation when both regulators are present.

8544 records 1/570 page Next 12345 下5页 Last page